A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with treatment-resistant depression.
Researchers tracked changes in a critical brain receptor that helps neurons communicate and found that ketamine reshapes its activity in specific brain regions tied to mood and reward.
These shifts strongly matched improvements in patients’ symptoms. The findings could help scientists develop better ways to predict who will benefit from ketamine therapy.
Read more
The U.S. Ketamine Clinic industry is growing fast.
This is because more people are looking for new ways to treat mental health problems. It’s already a $3.1B industry, but it’s expected to more than double over the next five years.
Read more
This ketamine trial for resistant depression shows positive results.
The study is the largest to date comparing generic ketamine with placebo in treating severe depression.
Read more
This article from The Guardian states: The ketamine industry, like the wide psychedelic industry, is experiencing growing pains.
One of the largest startup clinic chains offering ketamine treatment has just gone bust, another is in dire straits, and others face uncertainty.
Why are so many ketamine clinics struggling, even as demand is increasing?
Read more